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Abstract 
Ketamine is widely used in medicine in combination with several benzodiazepines including 
midazolam. The objectives of this study were to develop a novel HPLC-MS/SRM method 
capable of quantifying ketamine and norketamine using an isotopic dilution strategy in biological 
matrices and study the formation of norketamine, the principal metabolite of ketamine with and 
without the presence of midazolam, a well-known CYP3A substrate. The chromatographic 
separation was achieved using a Thermo Betasil Phenyl 100 x 2 mm column combined with an 
isocratic mobile phase composed of acetonitrile, methanol, water and formic acid (60:20:20:0.4) 
at a flow rate of 300 µL/min. The mass spectrometer was operating in selected reaction 
monitoring mode and the analytical range was set at 0.05–50 µM. The precision (%CV) and 
accuracy (%NOM) observed were ranging from 3.9–7.8 and 95.9.2–111.1% respectively. The 
initial rate of formation of norketamine was determined using various ketamine concentration and 
Km values of 18.4 µM, 13.8 µM and 30.8 µM for rat, dog and human liver S9 fractions were 
observed respectively. The metabolic stability of ketamine on liver S9 fractions was significantly 
higher in human (T1/2 = 159.4 min) compared with rat (T1/2 = 12.6 min) and dog (T1/2 = 7.3 min) 
liver S9 fractions. Moreover significantly lower IC50 and Ki values observed in human compared 
with rat and dog liver S9 fractions. Experiments with cDNA expressed CYP3A enzymes showed 
the formation of norketamine is mediated by CYP3A but results suggest an important 
contribution from others isoenzymes, most likely CYP2C particularly in rat. 
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Introduction 
Ketamine is a N-methyl-D-aspartate (NMDA) antagonist blocking glutamatergic functions, 
widely used in veterinary medicine in combination with xylazine [Stokes et al., 2009; Veilleux-
Lemieux et al. 2012; St-Germain Lavoie et al. 2013] and several benzodiazepines [Hall, 2012; 
Maruf et al., 2010; Cartwright and Pingel, 1984]. Ketamine is used in concomitance with 
midazolam for analgesia/sedation of adult and pediatric patients [Wood, 2013; Barkan et al., 
2013]. An exhaustive characterization of ketamine metabolism would provide the basis to foster a 
better understanding of possible drug-drug interactions in mammalians in order to prevent 
treatment failure or adverse effects resulting from possible alterations in drug metabolism when 
co-administered with other drugs. The impairment of drug metabolism resulting from enzymatic 
competition and inhibition has severe clinical implications as a result of an increased 
bioavailability and hampered clearance [Armstrong et al., 2009]. Recent in vitro metabolism 
studies revealed that ketamine is extensively metabolized to norketamine, dehydronorketamine, 
and 3-hydroxylated norketamine [Mössner et al. 2011; Kwan and Thormann, 2011]. These 
studies identified the cytochrome P450 (CYP) enzymes involved in the phase 1 metabolism of 
ketamine, principally CYP3A, and to a notably lesser extent CYP2C, CYP2B and CYP2D. 
Interestingly, historical data has shown that common metabolism by CYP3A enzymes have 
resulted in numerous clinically significant drug-drug interactions [Ogu and Maxa, 2000]. Thus, to 
explore possible drug-drug interactions, a comprehensive ketamine metabolism study in liver S9 
fractions and cDNA-expressed CYP3A enzymes is required. The liver S9 fraction contains both 
microsomal and cytosolic fractions enabling the study of phase I and phase II drug metabolism. 
Liver S9 fraction is widely used as a simple and rapid in vitro method to examine drug 
metabolism. cDNA-expressed CYP3A enzymes are readily available and will allow to study the 
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very specific metabolic pathway associated with the transformation of ketamine to norketamine, 
the main metabolite observed in vitro and in vivo [Desta et al., 2012; Capponi et al., 2009].      
Midazolam is a sedative drug with anxiolytic and amnestic properties with observed short-acting 
effects. It is widely used as a premedication in children [Barkan et al., 2013]. Midazolam is 
primarily metabolized in the liver by the CYP3A (CYP3A4 in human) to its pharmacologic 
active metabolite, α-hydroxymidazolam [Shimizu et al., 2007]. Moreover, α-hydroxymidazolam 
potency is comparable with the parent drug and contributes to the overall effect of midazolam. 
Midazolam is the preferred phenotyping CYP3A4 probe substrate used for in vitro and in vivo 
studies [Halama et al., 2013; Mooiman et al., 2013]. Co-administration of ketamine and 
midazolam to animals or humans could lead to competitive inhibition of CYP3A and result in an 
increase of systemic concentrations. Thus, it may produce significant adverse effects. It is 
therefore important to assess the potential of metabolic interactions particularly, interaction with 
CYP3A.  
There are some analytical methods available in the literature for the measurement of ketamine 
and its metabolites in several biological matrices including hair, urine and plasma [Lin et al., 
2013; Parkin et al., 2013; Moaddel et al., 2010]. Most of these published methods are used for 
forensic toxicology studies and they were not adapted, nor validated for metabolism studies. The 
method selectivity, precision and accuracy are critical in determining metabolic kinetic 
parameters.  The first objective of the current study was to develop a HPLC-MS/SRM method 
quantifying ketamine and norketamine in liver S9 fraction suspensions using an isotopic dilution 
strategy. The second objective was to determine the relative substrate affinity for the CYP3A and 
the metabolic stability of ketamine in rat, dog and human liver S9 fractions. A third objective was 
to estimate the inhibitory effect of midazolam on ketamine CYP3A metabolism and compare 
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with the preferred CYP3A inhibitor ketoconazole [Bourrié et al., 1996]. Finally, a forth objective 
was to confirm inhibition results using cDNA-expressed CYP3A enzymes. 
Materials and Methods 
Chemicals and Reagents 
Ketamine, d4-ketamine, norketamine, d4-norketamine and midazolam were obtained in solution 
from Cerilliant (Round Rock, TX). Ketoconazole (CYP3A inhibitor) was obtained from Sigma-
Aldrich (St Louis, MO, USA). Other chemicals, including acetonitrile, formic acid, methanol, 
sodium phosphate dibasic and sodium phosphate monobasic were purchased from Fisher 
Scientific (Ottawa, ON, Canada). Mammalian liver S9 fractions, cDNA-expressed CYP3A 
enzymes (SupersomesTM) and NADPH-regenerating system solutions were obtained from BD 
Biosciences (Woburn, MA, USA). S9 fractions and SupersomesTM were tested for activities with 
standard testing procedure prior usage.  
Quantitative Analytical Methods 
The concentrations of ketamine and norketamine were determined using an HPLC-MS/SRM 
assay. Briefly, 50 µL of matrix samples (i.e. 0.5 mg/mL liver S9 fraction suspension) were mixed 
with 250 µL of deuterated internal standard solution (1 µM of d4-ketamine and d4-norketamine in 
acetonitrile) in a 1.5 mL centrifuge tube. The samples were then vortexed vigorously and were 
allowed to rest for 10 min at room temperature prior to centrifugation. Samples were centrifuged 
at 12,000 g for 10 min and 200 µL of the supernatant was transferred into an injection vial. Two 
µL of samples were injected using a Perkin Elmer Series 200 HPLC (Shelton, CT) onto a Thermo 
Hypersil Phenyl 100 x 2 mm column (5µm) with flow rate of 300 µL/min. The mobile phase 
consisted of a mixture of acetonitrile, methanol, water and formic acid at a ratio of 60:20:20:0.4, 
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respectively. The AB SCIEX API 2000 QTRAP® mass spectrometer (Concord, Ontario, Canada) 
was interfaced with the HPLC system using a pneumatic assisted electrospray ion source. The 
nitrogen gas 1 was set to 25 PSI, the nitrogen gas 2 was set to 45 PSI and heated at 400˚C. The 
electrospray electrode was set to 5000V. The declustering potential (DP) was set to 25V and the 
collision energy (CE) was set to 30V. The selected reaction monitoring (SRM) transitions were 
set to m/z 238.1 → 125.0, 242.1 → 129.0, 224.1 → 125.0 and 228.1 → 129.0 for ketamine, d4-
ketamine, norketamine and d4-norketamine respectively. The dwell time was set to 100 msec and 
the pause time at 5 msec. The analytical range used was ranging from 0.05 to 50 µM. Standard 
and quality control samples were prepared in liver S9 enzyme suspensions but NADPH-
regeneration solution A and B were added after the precipitation with acetonitrile to avoid the 
degradation of ketamine. 
Liver S9 Fraction Incubation 
The incubations were performed as previously described [Lavoie et al., 2013] and were 
performed minimally in triplicate. The incubations were performed in a microcentrifuge tube and 
contained various concentrations ranging from 1 to 100 µM of ketamine, 0.5 mg/mL of S9 
fraction proteins diluted in 0.1 M phosphate buffer, pH 7.4. Liver S9 enzyme suspensions (total 
volume of 1 mL) were preincubated with 50 µL of NADPH-regenerating solution A (BD 
Biosciences Cat. No. 451220), 10 µL of solution B (BD Biosciences Cat. No. 451200), in 0.1 M 
phosphate buffer (pH 7.4) at 37°C for 5 min prior fortification with ketamine. Immediately after 
fortification of ketamine into the liver S9 fraction suspension containing the NADPH-
regeneration system, the sampling point for t = 0 was taken, and further sampling points were 
taken at 5, 15, 30, 45 and 60 min for metabolic stability experiments. For the determination of Km 
and Vmax, the concentration of norketamine was determined after 10 min incubation. Fifty µL of 
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samples were taken and mixed with 250 µL of the deuterated internal standard solution (1 µM of 
d4-ketamine and d4-norketamine in acetonitrile) in a 1.5 mL centrifuge tube. Samples were 
centrifuged at 12,000 g for 10 min and 200 µL of the supernatant was transferred into an injection 
vial for HPLC-MS/SRM analysis.  
Similarly, incubation of ketamine in liver S9 fractions at 30 µM with the presence of logarithmic 
concentrations of midazolam or ketoconazole was performed to determine IC50 value. Liver S9 
enzyme suspensions were preincubated with the NADPH regeneration system and midazolam or 
ketoconazole at various concentrations (0.01 µM to 1000 µM) for 5 min at 37˚C prior 
fortification with 30 µM of ketamine. Sampling points at 10 min were taken and 50 µL of 
samples were mixed with 250 µL of the deuterated internal standard solution (1 µM of d4-
ketamine and d4-norketamine in acetonitrile) in a 1.5 mL centrifuge tube. Samples were 
centrifuged at 12,000 g for 10 min and 200 µL of the supernatant was transferred into an injection 
vial for HPLC-MS/SRM analysis. 
cDNA Expressed CYP3A Incubation 
Incubation of ketamine in cDNA expressed CYP3A at 30 µM with the presence of logarithmic 
concentrations of midazolam or ketoconazole was used to determine IC50 values. cDNA 
expressed CYP3A enzyme suspensions (20 pmol/mL in 0.1 M phosphate buffer, pH 7.4) were 
preincubated with the NADPH regeneration system and midazolam or ketoconazole at various 
concentrations (0.01 µM to 1000 µM) for 5 min at 37˚C prior fortification with 30 µM of 
ketamine. Sampling points at 10 min were taken and 50 µL of samples were mixed with 250 µL 
of the deuterated internal standard solution (1 µM of d4-ketamine and d4-norketamine in 
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acetonitrile) in a 1.5 mL centrifuge tube. Samples were centrifuged at 12,000 g for 10 min and 
200 µL of the supernatant were transferred into an injection vial for HPLC-MS/SRM analysis. 
 
Data analysis and regression 
All non-linear regression analyses were performed with PRISM (6.0c) GraphPad software (La 
Jolla, CA) using the non-linear curve-fitting module with an estimation of the goodness of fit.  
The Michaelis-Menten equation describes the rates of irreversible enzymatic reactions that are 
generally observed for CYP mediated metabolic reactions. Michaelis-Menten parameters can be 
estimated by various linearization methods. However, non-linear regression analysis was 
performed using the Michaelis-Menten equation [Michaelis and Menten, 1913].  
𝑣! = !!"#  [!]!!!  [!]  (1) 
Were the initial velocity (vi) was determined using equation 2. 
𝑣! = ![!]!" = [!"#$%&'()!%]!"  !"#!"  !"#  (2) 
The initial rate (vi) was calculated based on the concentration norketamine measured after 10 
minutes incubation of ketamine in liver S9 enzyme or SupersomesTM suspensions. Following 
sample analysis, the analyte/deuterated internal standard peak area ratio was used to determine 
ketamine and norketamine concentrations at various time points to determine the metabolic 
stability. All depletion data were fitted to the monoexponential decay model described in 
equation (3) where C(t) are substrate concentration at time t and C0 is the initial concentration. 
𝐶(𝑡) = 𝐶!𝑒!!"  (3) 
In vitro half-life was obtained using equation (4):  
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𝑇!/! = !"(!)!   (4) 
Additionally, the enzyme-mediated clearance (CLuint) that would occur without physiological 
limitations including protein binding or hepatic blood flow was determined using equation (5). 
𝐶𝐿𝑢!"# = !!"#!!  (5) 
IC50 values for the inhibition of the formation of norketamine, the principal hepatic metabolite of 
ketamine were determined by nonlinear regression analysis using the following equation (6). 
𝑉! =   𝑉!  !"# + (   !!  !"#!!!  !"#!!!"(!"# ! !!"#$%!")  ) (6) 
Results and Discussion 
Tandem Mass Spectrometry 
Precursor ion and product ion mass spectra for ketamine, norketamine and deuterated analog 
internal standards were obtained in positive ion mode. The precursor ion spectra of ketamine and 
norketamine showed an intense signal for the protonated molecular ion ([M+H]+) at m/z 238 and 
m/z 224, respectively (Fig. 1A and Fig 1B). Precursor ions detected for d4-ketamine and d4-
norketamine were m/z 242 and m/z 228 respectively (data not shown).  The product ion spectrum 
of ketamine has predominant fragment ions at m/z 125, m/z 163 and m/z 179 (Fig. 1C). The 
product ion spectrum of norketamine has predominant fragment ions at m/z 125 and m/z 179 (Fig. 
1D). The deuterated analog internal standards showed an intense fragment ion at m/z 129 
compatible with the introduction of deuterium atoms on the benzene ring (data not shown).  The 
mass transition in SRM mode was set for best sensitivity and selectivity at m/z 238 → 125, 242 
→ 129, 224 → 125 and 228 → 129 for ketamine, d4-ketamine, norketamine and d4-norketamine 
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respectively. As illustrated in Fig. 1C and Fig. 1D, the product ion spectra were compatible with 
the molecular structures. The limit of detection, defined as being the quantity of analyte required 
to obtain 3-5 times the signal-to-noise ratio response, was established at 5 pg injected on column 
for both analytes using the SCIEX API 2000 QTRAP® equipped with a Turbo IonSprayTM source.  
Calibration Curve Analysis 
A linear regression (weighted 1/concentration) produced the best fit for the concentration–
detector relationship. The regression model used was determined using the sum of the squares of 
the deviations [Beaudry, 1999]. By convention, the regression line is considered to properly fit 
the calibration set when the sum of squares of the deviations is minimized. The calculated 
coefficients of correlation (r) were better then 0.998 for an analytical range set from 0.05 to 50 
µM in liver S9 enzyme suspensions.  
Precision and Accuracy 
The reproducibility of the method was evaluated by analyzing twelve replicates of liver S9 
enzyme suspension samples fortified with ketamine and norketamine at the nominal 
concentration of 0.1, 1 and 50 µM. The precision and accuracy results are displayed in Table 1. 
The results obtained demonstrate that acceptable precision and accuracy results were achieved 
and were compatible with generally accepted criteria in bioanalysis (CDER and CVM, 2001). A 
representative chromatogram of LOQ samples is shown in Fig. 2. As illustrated in Fig 2., 
extracted blank liver S9 fraction did not show any interference from endogenous substances at 
the mass transition monitored for ketamine and norketamine. Moreover, the signal-to-noise ratio 
of the LOQ sample was above 10:1 with a significant number of points to adequately determine 
peak area allowing the quantification these two analytes with acceptable figure of merits for a 
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metabolism study. This analytical method was also successfully adapted for analysis in rat 
plasma.  
Determination of the apparent Michaelis constant Km and Vmax 
The effect of substrate concentration on the initial rate (Vi) of an enzyme-catalyzed reaction is a 
fundamental concept in enzyme kinetics. The Michaelis constant Km of an enzyme represents the 
substrate concentration at which the reaction occurs at half of the maximum rate. Km is an 
indicator of the affinity that an enzyme has for a particular substrate, and hence the stability of 
the enzyme-substrate complex. Low Km value may suggest that enzyme has a greater affinity for 
substrate and vice-versa. To adequately determine the value of the apparent Michaelis-Menten 
constant Km as well as the maximum rate achieved by the system (Vmax), the data were fitted with 
the Michaelis-Menten equation (1). The initial rate (Vi) was calculated using the equation (2) and 
concentrations of norketamine were determined after 10 min ketamine incubation in liver S9 
fraction suspensions by HPLC-MS/SRM. Figure 3 shows results coherent with a kinetics 
following a Michaelis-Menten enzymatic reaction for all three species. The derived results from 
the regression analyses suggest Km values of 18.4 (± 2.3) µM, 13.8 (± 1.5) µM and 30.8 (± 7.1) 
µM for rat, dog and human liver S9 fractions respectively. It has been previously determined that 
the formation of norketamine is mainly mediated by CYP3A but other CYP enzymes are 
involved into the metabolism of ketamine [Mössner et al. 2011; Kwan and Thormann, 2011]. 
There is a two-fold difference between the apparent Km values observed in animal liver S9 
fractions compared with human liver S9 fractions. This is interesting since Km is an indicator of 
the stability of the enzyme-substrate complex. A lower Km may indicate that the substrate might 
be less susceptible to competitive inhibition in animal species compared with human. This is 
interesting since hepatic drug clearance depend on hepatic blood flow rate but also on the 
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extraction coefficient. The extraction coefficient will be altered in the context of competitive 
inhibition and will significantly impact drug exposition. These early results may suggest that 
CYP3A mediated ketamine metabolism will be less susceptible to competitive inhibition in rat 
and dog compared to human.    
Ketamine metabolic stability evaluations in mammalian liver S9 fractions 
Metabolism is a key element of drug clearance and it directly influences the systemic drug 
exposure. Ketamine metabolic stability at 5 µM ([S] < Km) was evaluated in rat, dog and human 
liver S9 fractions. The data presented in Fig. 4 were fitted with a mono-exponential decay model 
as described in equation (3) and the coefficients of determination (R2) were comprised between 
0.88 and 0.99 for each fitted data series, suggesting that ketamine first-order kinetics was 
observed and the condition of the model was met [Masimirembwa et al., 2001]. The in vitro T1/2 
derived were 12.6 (± 0.4) min, 7.3 (± 1.0) min and 159.4 (± 29.8) min in rat, dog and human liver 
S9 fractions respectively. There is an important discrepancy between the metabolic fate observed 
in human liver S9 fractions compared to rat and dog liver S9 fractions. If the in vitro difference 
observed translate in vivo, drug exposition will therefore be considerably different between 
species. Presently the pharmacokinetic data available from the literature are difficult to compare 
since dose, formulation, route of administration and regiment are inconsistent. Thus, we are 
unable to make a thoughtful comparison with our in vitro results. However, in all species, total 
clearance observed is relatively high but the terminal half-life is longer in human compared to 
rodents [Clements et al., 1982; Veilleux-Lemieux et al. 2013]. During the elimination phase, the 
plasma concentration is specifically linked with the elimination of ketamine from the body and 
the elimination is then considered independent of the amount of drug remaining. Consequently, 
the difference in terminal half-life observed in vivo is compatible with our in vitro results despite 
 13 
their dissimilarity. The derived intrinsic clearance (CLuint) data presented in Table 2 suggest that 
the extent of ketamine CYP3A metabolism is reduced extensively in human liver S9 fractions 
compared to rat and dog liver S9 fractions suggesting that ketamine exposition in human could be 
significantly higher using an equivalent dose, formulation and route of administration. However, 
there are various elements affecting drug elimination other then liver phase 1 metabolism.  
Evaluation of the effect of midazolam and ketoconazole on ketamine CYP3A mediated 
metabolism  
Ketamine-midazolam is amongst the most frequently used anesthetic mixtures used in veterinary 
and human medicine. Interestingly, children patients receiving intravenous ketamine with 
midazolam for sedation show more pronounced adverse effects with patients younger than 10 
years [Wathen et al., 2000]. Dosing infants and children is impeded by a general lack of 
knowledge about drug bioavailability and disposition in this specific population particularly when 
concomitant drugs are used as anesthetic mixtures. In a previous study [Lavoie et al., 2013], we 
demonstrated that CYP3A xylazine metabolism was hampered by ketamine and ketoconazole in 
rat liver microsomes. The ketamine-xylazine combination is also commonly used and the 
impairment of drug metabolism resulting from enzymatic competitive inhibition may have severe 
clinical implications as a result of an increased bioavailability and hampered clearance [Lavoie et 
al., 2013; Veilleux-Lemieux et al., 2012]. In vitro metabolism studies revealed that the principal 
hepatic metabolite of ketamine was norketamine and the formation was principally catalyzed by 
CYP3A [Mössner et al. 2011; Kwan and Thormann, 2011].  Hence, midazolam is a well-
characterized CYP3A substrate used for in vitro and in vivo metabolism studies [Halama et al., 
2013; Mooiman et al., 2013]. One objective was to verify if midazolam could affect ketamine 
metabolism in rat, dog and human S9 liver fractions. As displayed in Figure 5 A, C and E, the 
determinations of midazolam IC50 suggest that indeed, midazolam can inhibit the formation of 
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norketamine, the main metabolite of ketamine. Moreover, as shown in Table 2, the calculated 
inhibition constant (Ki) suggest that midazolam inhibition was notably more important in human 
liver S9 fractions compared with rat and dog liver S9 fractions. This observation was also 
compatible with data obtained for cDNA expressed CYP3A enzymes as illustrated in Fig. 6 A, C 
and E.  Also, the Fig. 5 A, C and E revealed that midazolam can completely inhibit the formation 
of norketamine at concentrations beyond IC50. However, as shown in Fig. 5 B, D and F, 
ketoconazole, a well established CYP3A inhibitor, did not completely inhibit the formation of 
norketamine even at concentrations considerably higher then IC50. These results are compatible 
with a previous ketamine metabolism study performed with canine, equine and human liver 
microsomes [Mössner et al. 2011]. Additional experiments were conducted using cDNA 
expressed CYP3A enzymes and results shown in Fig.6 demonstrate that midazolam and 
ketoconazole were able to completely inhibit the formation of norketamine. This is an interesting 
result suggesting that the formation of norketamine in liver S9 fractions is not only mediated by 
CYP3A. Midazolam metabolism is primarily mediated by CYP3A, but a non-negligible CYP2C 
contribution was shown in recent studies [van Waterschoot et al. 2008]. Remarkably, the relative 
concentrations of individual P450 enzymes are different between rat and human favoring CYP2C 
in rat. This may explain why ketoconazole did not completely inhibit the formation of 
norketamine, particularly in rat liver S9 fractions were the rate of norketamine formation was still 
very high but midazolam was able to inhibit completely the formation of norketamine. Besides, 
derived Ki values suggest that ketoconazole is a much stronger inhibitor of CYP3A metabolism 
compared to midazolam, particularly in human liver S9 fractions and cDNA express human 
CYP3A4.  
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Mutual competitive inhibition caused by co-administration of drugs, may contribute to improve 
bioavailability in certain cases and this is one major reason the concomitance administration of 
ketamine and midazolam is an effective method for sedation and analgesia. A recent study 
demonstrated that combined ketamine-midazolam provided better results then midazolam alone 
for sedation of young children [Moreira et al., 2013]. But, children patients younger then 10 years 
receiving intravenous ketamine along with midazolam display more pronounced adverse effects 
[Wathen et al., 2000]. Drug-drug interactions have become an important issue in health care and 
concomitant drug administration is widely recognized to be a major cause. It is just in the last 
decade that evidences of major pharmacokinetic interactions between drugs were shown to be 
associated to hepatic CYP enzymatic metabolism interactions and more specifically, resulting 
from competitive inhibition. Drug-drug interactions may have severe consequences particularly 
anesthetized patients due to hemodynamic effects of anesthetic drugs and reduced renal clearance. 
Anaesthetic protocols in veterinary and human medicine often use multiple drugs to obtain the 
desired level of sedation and anesthesia. It is therefore important to investigate potential 
metabolism interactions since only limited data are available in specific patient subpopulations 
and animals. Genetic polymorphism of CYP3A and CYP2C may also contribute to aggravate 
drug-drug interactions in subpopulations and very little data on animal genetic polymorphism 
exist. Our results clearly demonstrate interactions between ketamine and midazolam metabolism. 
It is important to denote that our results show that midazolam has significantly more inhibitory 
effects on ketamine metabolism in human liver S9 fractions. This may explain the reason the 
administration of ketamine and midazolam in adult patient is considered very safe but more 
adverse effects were observed in young children.    
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Conclusion 
A novel high-performance liquid chromatographic-mass spectrometry SRM method was 
developed to quantify ketamine and norketamine. The novel method meets all requirements of 
specificity, sensitivity, linearity, precision and accuracy generally accepted in bioanalytical 
chemistry (CDER and CVM, 2001). In vitro metabolism studies were performed in rat, dog and 
human liver S9 fractions and cDNA expressed CYP3A enzymes. The data presented in this 
manuscript revealed that ketamine has a low affinity for CYP3A particularly in human liver S9 
fractions. The metabolic stability of ketamine on liver S9 fractions was significantly higher in 
human liver S9 fractions compared with rat and dog liver S9 fractions. This result may suggest 
that concomitant administration of ketamine with other drugs in human appear to be more 
susceptible to drug-drug interactions. This is confirmed with significantly lower IC50 and Ki 
values observed in human compared with rat and dog liver S9 fractions. Further experiments with 
ketamine, midazolam and ketoconazole strongly supported that the metabolism of ketamine to its 
main metabolite norketamine is mediated by CYP3A in rat, dog and human liver S9 fractions. 
Although, results also suggest the contribution of other isoforms, most likely CYP2C. The 
involvement of CYP3A and CYP2C in ketamine metabolism suggest that further 
pharmacokinetic studies in subpopulations would be required to assure a more define, predictable 
potency and a better control of side effects particularly in the context of concomitant 
administration of ketamine. Dose adjustments might be required when using ketamine with other 
analgesic, anesthetic and/or sedative drugs to avoid potential undesired drug-drug interactions. 
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Table 1. Determination of the precision and accuracy for the analysis of ketamine and 
norketamine in S9 liver fractions1 by HPLC-MS/MRM 
  Concentration (µM)  
 0.1 1 50 
 Intra-assay precision and accuracy (Run 1) 
Ketamine    
n 4 4 4 
Mean 0.113 1.10 47.2 
SD 0.0101 0.125 2.21 
% NOM 112.9% 109.9% 94.4% 
% CV 9.0% 11.3% 4.7% 
    
Norketamine    
n 4 4 4 
Mean 0.111 1.13 48.1 
SD 0.00856 0.104 2.33 
% NOM 111.0% 112.5% 96.1% 
% CV 7.7% 9.2% 4.8% 
 
 Intra-assay precision and accuracy (Run 2) 
Ketamine    
n 4 4 4 
Mean 0.111 1.12 47.9 
SD 0.00945 0.0888 1.34 
% NOM 111.1% 112.2% 95.7% 
% CV 8.5% 7.9% 2.8% 
    
Norketamine    
n 4 4 4 
Mean 0.110 1.11 48.2 
SD 0.00893 0.0749 1.35 
% NOM 109.8% 110.9% 96.4% 
% CV 8.1% 6.8% 2.8% 
 
 Intra-assay precision and accuracy (Run 3) 
Ketamine    
n 4 4 4 
Mean 0.109 1.08 48.8 
SD 0.00608 0.0518 2.02 
% NOM 109.4% 108.5% 97.6% 
% CV 5.6% 4.8% 4.1% 
    
Norketamine    
n 4 4 4 
Mean 0.106 1.09 48.3 
SD 0.00207 0.0522 3.47 
% NOM 105.9% 109.2% 96.6% 
% CV 2.0% 4.8% 7.2% 
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1 Precision and accuracy evaluations were performed using rat S9 fraction supernatant.  
 
  
 Inter-assay precision and accuracy 
Ketamine    
n 12 12 12 
Mean 0.111 1.10 48.0 
SD 0.00803 0.0859 1.85 
% NOM 111.1 % 110.2 % 95.9 % 
% CV 7.2 % 7.8 % 3.9 % 
    
Norketamine    
n 12 12 12 
Mean 0.109 1.11 48.2 
SD 0.00694 0.0735 2.30 
% NOM 108.9 % 110.9 % 96.4 % 
% CV 6.4 % 6.6 % 4.8 % 
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Table 2. Kinetic parameters associated with the formation norketamine in liver S9 fractions 
and cDNA express CYP3A enzymes.  
 
 Vmax Km CLuint IC501 Ki2 IC501 Ki2 
 nmol min-1 mg-1 µM 
(nmol mL-1) 
 Midazolam Ketoconazole 
Rat liver S9 3.16(± 0.13) 18.4(±2.3) 0.172 33.4(±1.6) 12.7 9.9(±1.5) 3.8 
Dog liver S9  2.05(±0.07) 13.8 (±1.5) 0.149 46.6(±1.5) 14.7 1.42(±0.18) 0.45 
Human liver S9 0.39 (±0.04) 30.8 (±7.1) 0.013 9.4(±0.6) 4.8 0.43(±0.15) 0.22 
        
Rat cDNA CYP3A1 19.3(±0.3)  8.9(±0.9)  
Rat cDNA CYP3A2 24.5(±0.9)  7.3(±1.0)  
Dog cDNA CYP3A12 35.3(±2.6  0.90(±0.22)  
Human cDNA CYP3A4 5.4(±0.9)  0.23(±0.10)  
 
1 The substrate concentration was 30µM 
2 Determination of Ki was based in this formula:  𝐾! = !"!"!! [!]!! 
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Figure legends 
Figure 1. Precursor (MS) and product ion spectra (MS2) of ketamine (A and C) and norketamine 
(B and D).  
Figure 2. HPLC-MS/SRM analysis of ketamine and norketamine in liver S9 fractions. Overlay 
SRM extracted ion chromatograms of a reference (ref), a blank sample (black) and an extracted 
liver S9 fraction LOQ samples (blue) for ketamine (A) and norketamine (B).  
Figure 3. Determination of Michaelis constant Km and maximum velocity Vmax using non-linear 
regression fitting. Each point represents the mean (±SD) of triplicate experiments. 
Figure 4. Depletion profile of ketamine in rat, dog and human liver S9 fractions rat at 5 µM. Data 
presented on a linear scale and each point represents the mean (±SD) of triplicate experiments. 
Figure 5. Determination of the inhibitory concentration 50% (IC50) of midazolam and 
ketoconazole on the formation of norketamine in rat (A and B), dog (C and D) and human (E and 
F) liver S9 fractions. Each point represents mean (±SD) of triplicate experiments.  
Figure 6. Determination of the inhibitory concentration 50% (IC50) of midazolam and 
ketoconazole on the formation of norketamine in cDNA express rat CYP3A1 and CYPA 3A2 (A 
and B), dog CYP 3A12 (C and D) and human CYP3A4 (E and F). Each point represents mean 
(±SD) of triplicate experiments. 
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